Study: NCT01319981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSLI
Description: 2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSLI
Description: 2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Medrol
Description: 40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10\^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10\^9/L by day 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10\^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10\^9/L by day 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7